![](https://www.molecular-medicine-israel.co.il/wp-content/uploads/2018/02/fx1-1-300x300.jpg)
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Highlights •Wild-type KRAS expression affects cellular fitness in KRAS mutant LUAD •Wild-type KRAS expression impairs response to MEK inhibitors in KRAS mutant LUAD •Wild-type KRAS